Core Insights - SciSparc Ltd. has acquired an IP portfolio from Xylo Technologies, including the MUSE™ system, targeting the global multi-billion dollar GERD device market [1][4] - The MUSE™ system is designed for transoral fundoplication, a minimally invasive procedure for treating gastroesophageal reflux disease (GERD) [2] - SciSparc plans to commercialize these technologies immediately and aims for rapid market penetration and revenue generation [2] Market Opportunity - The global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, with a CAGR of 3.24% from 2025 to 2030 [5] - SciSparc intends to replicate Xylo's successful commercialization model from Greater China in high-growth regions like North America, Europe, and Latin America [3] Acquisition Details - SciSparc acquired the complete portfolio of patents and related intellectual property rights associated with the MUSE™ system, issuing shares that represent 19.99% of its outstanding share capital to Xylo [4]

Core Insights - SciSparc Ltd. has signed a definitive agreement to acquire a portfolio of patents, trademarks, and intellectual property rights for innovative endoscopic systems, including the MUSE™ system, from Xylo Technologies Ltd. [1][4] - The MUSE™ system is designed for transoral fundoplication, a minimally invasive procedure for treating gastroesophageal reflux disease (GERD) [2] - SciSparc plans to commercialize these technologies immediately after the transaction closes, aiming for rapid market penetration and revenue generation [2] Company Strategy - Building on Xylo's previous success in Greater China, where it generated $3 million through a licensing agreement, SciSparc intends to replicate this model in high-growth markets such as North America, Europe, and Latin America [3] - The company aims to establish exclusive partnerships with leading regional distributors to accelerate global commercialization and unlock significant revenue streams [3] Financial Terms - As part of the acquisition, SciSparc will issue ordinary shares to Xylo, representing 19.99% of the issued and outstanding share capital of SciSparc upon closing, scheduled for March 8, 2026 [4] - The transaction is subject to customary closing conditions, including regulatory approvals [5] Market Context - The global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, with a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030 [5]

Core Insights - SciSparc Ltd. has signed a binding term sheet to acquire patents, trademarks, and intellectual property rights for innovative endoscopic systems, including the MUSE™ system, from Xylo Technologies Ltd. [1][4] Company Overview - SciSparc operates through its majority-owned subsidiary NeuroThera Labs Inc., focusing on clinical-stage pharmaceutical developments, particularly in cannabinoid pharmaceuticals [7]. Product Details - The MUSE™ system is a single-use endoscopic device designed for transoral fundoplication, a minimally invasive procedure for treating gastroesophageal reflux disease (GERD) [2]. Market Strategy - Following Xylo's successful commercialization in Greater China, SciSparc aims to replicate this model in high-growth regions like North America, Europe, and Latin America by forming exclusive partnerships with regional distributors [3]. Financial Terms of Acquisition - The acquisition will involve SciSparc issuing shares to Xylo, representing 19.99% of the company's issued and outstanding share capital upon closing of definitive agreements [4]. Market Potential - The global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to grow to $3.03 billion by 2030, with a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030 [5].

Core Viewpoint - SciSparc Ltd. has signed a binding term sheet to acquire a portfolio of patents, trademarks, and intellectual property rights related to innovative endoscopic systems, including the MUSE™ system, from Xylo Technologies Ltd. This acquisition aims to enhance SciSparc's capabilities in the medical device market, particularly for treating gastroesophageal reflux disease (GERD) [1][4]. Company Overview - SciSparc Ltd. operates through its majority-owned subsidiary NeuroThera Labs Inc., focusing on clinical-stage pharmaceutical developments, particularly in cannabinoid pharmaceuticals [7]. - The company is engaged in drug development programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder (ASD) [7]. Acquisition Details - The acquisition includes the complete portfolio of intellectual property rights associated with the MUSE™ system, which is designed for transoral fundoplication, a minimally invasive procedure for GERD treatment [2][4]. - In exchange for the acquired assets, SciSparc will issue shares representing 19.99% of its outstanding share capital to Xylo upon closing of definitive agreements [4]. Market Potential - The global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to grow to $3.03 billion by 2030, with a compound annual growth rate (CAGR) of 3.24% from 2025 to 2030 [5]. - SciSparc plans to replicate Xylo's successful commercialization model from Greater China to high-growth regions such as North America, Europe, and Latin America through exclusive partnerships with regional distributors [3].